Member Info for Bebeto

By my reckoning, I'm expecting results from the hospital part of the trial around the 16th of July 2020.

Happy to let the Maiden Resource Estimate do all the pumping for me, sit tight and enjoy the ride.

Just minor pullback (for Eddie) you'll be ok

Looking good for results, shame I didn't buy more lower. Onwards and upwards

They only have 109 participants data in the COPD trial, which would usually take around 3 weeks to analyse and verify.

It looks to me, that they have to do for a far more comprehensive trial and using some of the COPD trial data, to get earlier preliminary results in order to obtain funds from other sources than placings.

Looking good though. IMO

Agree, looking forward to it . The rest of this year and 2021 should be interesting.

Wonder if it's to do with ESL ending up with such a large impairment charge.?

Shareprice can keep moving up too.

Remdesivir is for seriously ill patients, where's SNG001 will be for a primary response with possibly billions more doses.

Take note,( Russell Group) University of Southampton is going to be worldwide famous, for their breakthroughs in 2020.

Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of
Southampton and Trial Chief Investigator, commented: “Expansion of the SG016
placebo controlled trial where we will be treating patients at the first sign of COVID-19
symptoms is something of a first and reflects the ingenuity and expertise of Synairgen
and our researchers here at the University of Southampton. This novel approach is
designed to reduce infection risks for both patients and front-line workers. Critically, it
also allows us to gather clinical evidence for SNG001 more quickly, a treatment we
believe could play a crucial role in tackling the COVID-19 pandemic.”

There's the presence of 24 respiratory pathogens as co-infections in COVID-19 patients. Most of these co-infections occurred 1–4 days after the onset of disease in COVID-19 patients.The proportion of viral co-infections, fungal co-infections and bacterial-fungal co-infections were the highest in severe COVID-19 cases.

Interferon is used for the treatment of these co-infections.

It not a deramp at all, it's that or the whole of GGP sold to Newcrest otherwise there's no real value to shareholders. If they just sell Havieron the MCAP will rise to the price but when they start spending the money the MCAP is sure to follow.

We're in a very lucky position regarding Havieron and I'm more than happy to hold and see this one through, I've already done extremely well here.

GH with his CV & pedigree, he's the money man make no mistake.

It takes 10 seconds to look through the balance sheet to realise, the company is loss making, has no revenues (apart from interest of cash) and it can only exist through share dilution of some description, including no more grants from Govt of Western Australia either. This is the reality not a deramp.

The 5% fair market value, was a master stroke by GH, it gives GGP the flexibility to keep all options on the table. If one of the options was to spin-out another company to become GGP mining, then it would only be a on "paper" company as Newcrest would do all the mining and GGP would just pay a toll. This company would be profitable unlike the loss making exploration side, and no doubt GH would be very aware of that upside advantage.

Clearly there are other options available but this one cannot be ruled out at this stage

Looking forward to MRE from Newcrest.

We could well be looking at Greatland Gold Exploration Plc and Greatland Gold Mining Plc.

It's in the chairman's statement.

A spinoff is the creation of a new, public company out of a current public company.
A spinoff can occur when the new company is expected to be more profitable alone than it would otherwise be under the parent company.

The spinoff of a division or subsidiary into a new, independent company means that the new company takes with it all the assets and employees that it had under the parent company. These assets can include products, production lines, and technologies. In some cases, the spun-off entity must take on new debt to pay the parent company for all of those assets.

" advancing exploration across our key assets and seeking opportunities to monetise those key exploration assets whether through sale, joint venture or spin-out via initial public offering."

There's more than two options on the table.

There's only a handful of ways the GGP/Havieron story could possibly turn out and each one is viable.

Newcrest has set down a 45km radius (could be more), to toll process everything through Telfer.

All will be revealed in good time.

The three most frequent micro-organisms that co-infected Covid-19 patients have are :
Streptococcus pneumoniae, Klebsiella pneumoniae & Haemophilus influenzae.

Newcrest are all over Havieron, steaming through phase 3 and they won't miss anything there, it's comfortably in the bag now.

GGP, I suspect that they might add a few blocks to their portfolio soon.

Anything else is anyone's guess.

Great posts Ghia,

According to the eu trial register, the 75% of the participants are aged 65 and over, so it would be fair to assume that home trials could also refer to care homes too.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/